Initiation (new start) criteria: Non-formulary tegaserod (Zelnorm) will be covered on the prescription drug benefit when the following criteria are met:

- Diagnosis of irritable bowel syndrome with constipation (IBS-C)
- Prescriber is a Gastroenterologist
- Patient is a female age 18 to 64
- Patient has had an inadequate response to a trial of at least 4 weeks duration, or intolerance to scheduled doses of the following medications:
  - A fiber supplement: psyllium fiber (Metamucil) or methylcellulose (Citrucel)
  - An osmotic laxative: Polyethylene glycol (MiraLAX) or lactulose
  - Lubiprostone (criteria based)
  - Linaclotide (criteria based)
- An estimated glomerular filtration rate (eGFR) of 15 mL/minute/1.73 m² or greater
- No evidence of moderate or severe hepatic impairment (Child-Pugh class B or C)
- No history of any of the following: bowel obstruction, symptomatic gallbladder disease, sphincter of Oddi dysfunction, abdominal adhesions, ischemic colitis, intestinal ischemia, heart attack, stroke, transient ischemic attack, or angina.

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary tegaserod (Zelnorm) will be covered on the prescription drug benefit when the following criteria are met:

- Diagnosis of irritable bowel syndrome with constipation (IBS-C)
- Prescriber is a Gastroenterologist
- Patient is a female age 18 to 64 years of age.
- Patient reports had an inadequate response to the following medications:
  - A fiber supplement: Psyllium fiber (Metamucil) or methylcellulose (Citrucel)
  - An osmotic laxative: Polyethylene glycol (MiraLAX) or lactulose
  - Lubiprostone (criteria based)
  - Linaclotide (criteria based)
- Patient reports no history of any of the following: severe kidney impairment, liver impairment, bowel obstruction, symptomatic gallbladder disease, sphincter of Oddi dysfunction, abdominal adhesions, ischemic colitis, intestinal ischemia, heart attack, stroke, transient ischemic attack, or angina.